Skip to main content
Top
Published in: Annals of Surgical Oncology 11/2014

01-10-2014 | Breast Oncology

Proactive Approach to Lymphedema Risk Reduction: A Prospective Study

Authors: Mei R. Fu, PhD, RN, ACNS-BC, FAAN, Deborah Axelrod, MD, FACS, Amber A. Guth, MD, FACS, Francis Cartwright, PhD, RN-BC, Zeyuan Qiu, PhD, Judith D. Goldberg, ScD, June Kim, MPS, Joan Scagliola, MS, RN, Robin Kleinman, MS, RN, Judith Haber, PhD, RN, APRN-BC, FAAN

Published in: Annals of Surgical Oncology | Issue 11/2014

Login to get access

Abstract

Background

Advances in cancer treatments continue to reduce the incidence of lymphedema. Yet, many breast cancer survivors still face long-term postoperative challenges as a result of developing lymphedema. The purpose of this study was to preliminarily evaluate The Optimal Lymph Flow program, a patient-centered education and behavioral program focusing on self-care strategies to enhance lymphedema risk reduction by promoting lymph flow and optimize body mass index (BMI).

Methods

A prospective, longitudinal, quasi-experimental design with repeated-measures was used. The study outcomes included lymph volume changes by infrared perometer, and BMI by a bioimpedance device at pre-surgery baseline, 2–4 weeks after surgery, 6-month and 12-month follow-up. A total of 140 patients were recruited and participated in The Optimal Lymph Flow program; 134 patients completed the study with 4 % attrition rate.

Results

Fifty-eight percent of patients had axillary node dissection and 42 % had sentinel lymph node biopsy (SLNB). The majority (97 %) of patients maintained and improved their preoperative limb volume (LV) and BMI at the study endpoint of 12 months following cancer surgery. Cumulatively, two patients with SLNB and two patients with axillary lymph node dissection had measurable lymphedema (>10 % LV change). At the 12-month follow-up, among the four patients with measurable lymphedema, two patients’ LV returned to preoperative level without compression therapy but by maintaining The Optimal Lymph Flow exercises to promote daily lymph flow.

Conclusions

This educational and behavioral program is effective in enhancing lymphedema risk reduction. The study provided initial evidence for emerging change in lymphedema care from treatment-focus to proactive risk reduction.
Literature
1.
go back to reference Fu MR, Ridner SH, Hu SH, et al. Psychosocial impact of lymphedema: a systematic review of literature from 2004 to 2011. Psychooncol. 2013;22(7):1466-84.CrossRef Fu MR, Ridner SH, Hu SH, et al. Psychosocial impact of lymphedema: a systematic review of literature from 2004 to 2011. Psychooncol. 2013;22(7):1466-84.CrossRef
2.
go back to reference Chachaj A, Malyszczak K, Pyszel K, et al. Physical and psychological impairments of women with upper lymphedema following breast cancer treatment. Psychooncol. 2009;19:299–305.CrossRef Chachaj A, Malyszczak K, Pyszel K, et al. Physical and psychological impairments of women with upper lymphedema following breast cancer treatment. Psychooncol. 2009;19:299–305.CrossRef
3.
go back to reference Petrek JA, Senie RT, Peters M, Rosen PP. Lymphedema in a cohort of breast carcinoma survivors 20 years after diagnosis. Cancer. 2001;92(6):1368–77.PubMedCrossRef Petrek JA, Senie RT, Peters M, Rosen PP. Lymphedema in a cohort of breast carcinoma survivors 20 years after diagnosis. Cancer. 2001;92(6):1368–77.PubMedCrossRef
4.
5.
go back to reference International Society of Lymphology. The diagnosis and treatment of peripheral lymphedema. Consensus document of the International Society of Lymphology. Lymphology. 2003;36:84–91. International Society of Lymphology. The diagnosis and treatment of peripheral lymphedema. Consensus document of the International Society of Lymphology. Lymphology. 2003;36:84–91.
6.
go back to reference Stanton AW, Modi S, Mellor RH, et al. Recent advances in breast cancer-related lymphedema of the arm: lymphatic pump failure and predisposing factors. Lymphat Res Biol. 2009;7(1):29–45.PubMedCrossRef Stanton AW, Modi S, Mellor RH, et al. Recent advances in breast cancer-related lymphedema of the arm: lymphatic pump failure and predisposing factors. Lymphat Res Biol. 2009;7(1):29–45.PubMedCrossRef
7.
go back to reference Brorson H, Aberg M, Svensson H. Chronic lymphedema and adipocyte proliferation: clinical therapeutic implications. The Lymphatic Continuum. National Institutes of Health, Bethesda, USA, 2002. Lymphat Res Biol. 2003;1:88. Brorson H, Aberg M, Svensson H. Chronic lymphedema and adipocyte proliferation: clinical therapeutic implications. The Lymphatic Continuum. National Institutes of Health, Bethesda, USA, 2002. Lymphat Res Biol. 2003;1:88.
8.
go back to reference Mak SS, Yeo W, Lee YM, et al. Predictors of lymphedema in patients with breast cancer undergoing axillary lymph node dissection in Hong Kong. Nurs Res. 2008;57:416-25.PubMedCrossRef Mak SS, Yeo W, Lee YM, et al. Predictors of lymphedema in patients with breast cancer undergoing axillary lymph node dissection in Hong Kong. Nurs Res. 2008;57:416-25.PubMedCrossRef
9.
go back to reference Kwan ML, Darbinian J, Schmitz KH, et al. Risk factors for lymphedema in a prospective breast cancer survivorship study: the Pathways Study. Arch Surg. 2010;145:1055–63.PubMedCrossRefPubMedCentral Kwan ML, Darbinian J, Schmitz KH, et al. Risk factors for lymphedema in a prospective breast cancer survivorship study: the Pathways Study. Arch Surg. 2010;145:1055–63.PubMedCrossRefPubMedCentral
10.
go back to reference Ahmed RL, Schmitz KH, Prizment AE, et al. Risk factors for lymphedema in breast cancer survivors, the Iowa Women’s Health Study. Breast Cancer Res Treat. 2001;130:981–91.CrossRef Ahmed RL, Schmitz KH, Prizment AE, et al. Risk factors for lymphedema in breast cancer survivors, the Iowa Women’s Health Study. Breast Cancer Res Treat. 2001;130:981–91.CrossRef
11.
go back to reference Paskett ED, Naughton MJ, McCoy TP, et al. The epidemiology of arm and hand swelling in premenopausal breast cancer survivors. Cancer Epidemiol Biomarkers Prev. 2007;16:775–82.PubMedCrossRef Paskett ED, Naughton MJ, McCoy TP, et al. The epidemiology of arm and hand swelling in premenopausal breast cancer survivors. Cancer Epidemiol Biomarkers Prev. 2007;16:775–82.PubMedCrossRef
12.
go back to reference Ruocco V, Schwartz RA, Ruocco E. Lymphedema: an immunologically vulnerable site for development of neoplasms. J Am Acad Dermat. 2002;47:124–7.CrossRef Ruocco V, Schwartz RA, Ruocco E. Lymphedema: an immunologically vulnerable site for development of neoplasms. J Am Acad Dermat. 2002;47:124–7.CrossRef
13.
go back to reference Fu MR, Chen C, Haber J, et al. The effect of providing information about lymphedema on the cognitive and symptom outcomes of breast cancer survivors. Ann Surg Oncol. 2010;17(7):1847–53.PubMedCrossRef Fu MR, Chen C, Haber J, et al. The effect of providing information about lymphedema on the cognitive and symptom outcomes of breast cancer survivors. Ann Surg Oncol. 2010;17(7):1847–53.PubMedCrossRef
15.
go back to reference Nielsen I, Gordon S, Selby A. Breast cancer-related lymphoedema risk reduction advice: a challenge for health professionals. Cancer Treat Rev. 2008;34(7):621–8.PubMedCrossRef Nielsen I, Gordon S, Selby A. Breast cancer-related lymphoedema risk reduction advice: a challenge for health professionals. Cancer Treat Rev. 2008;34(7):621–8.PubMedCrossRef
16.
go back to reference Stout NL, Binkley JM, Schmitz KH, Andrews K, Hayes SC, Campbell KL, et al. A prospective surveillance model for rehabilitation for women with breast cancer. Cancer. 2012;118(8 Suppl):2191–200.PubMedCrossRef Stout NL, Binkley JM, Schmitz KH, Andrews K, Hayes SC, Campbell KL, et al. A prospective surveillance model for rehabilitation for women with breast cancer. Cancer. 2012;118(8 Suppl):2191–200.PubMedCrossRef
17.
go back to reference Armer JM, Stewart BR. A comparison of four diagnostic criteria for lymphedema in a post-breast cancer population. Lymphat Res Biol. 2005;3:208–17.PubMedCrossRef Armer JM, Stewart BR. A comparison of four diagnostic criteria for lymphedema in a post-breast cancer population. Lymphat Res Biol. 2005;3:208–17.PubMedCrossRef
18.
go back to reference McLaughlin SA, Bagaria S, Gibson T, et al. Trends in risk reduction practices for the prevention of lymphedema in the first 12 months after breast cancer surgery. J Am Coll Surg. 2013:216:380–9.PubMedCrossRef McLaughlin SA, Bagaria S, Gibson T, et al. Trends in risk reduction practices for the prevention of lymphedema in the first 12 months after breast cancer surgery. J Am Coll Surg. 2013:216:380–9.PubMedCrossRef
19.
go back to reference Lasinski BB, Thrift KM, Squire D, et al. A systematic review of the evidence for complete decongestive therapy in the treatment of lymphedema from 2004 to 2011. PM R. 2012;4(8):580–601.PubMedCrossRef Lasinski BB, Thrift KM, Squire D, et al. A systematic review of the evidence for complete decongestive therapy in the treatment of lymphedema from 2004 to 2011. PM R. 2012;4(8):580–601.PubMedCrossRef
20.
go back to reference American Cancer Society. Breast Cancer Facts & Figures 2013-2014. Atlanta: American Cancer Society, Inc.; 2013. American Cancer Society. Breast Cancer Facts & Figures 2013-2014. Atlanta: American Cancer Society, Inc.; 2013.
21.
go back to reference Shih YC, Xu Y, Cormier JN, et al. Incidence, treatment costs, and complications of lymphedema after breast cancer among women of working age: a 2-year follow-up study. J Clin Oncol. 2009;27(12):2007–14.PubMedCrossRef Shih YC, Xu Y, Cormier JN, et al. Incidence, treatment costs, and complications of lymphedema after breast cancer among women of working age: a 2-year follow-up study. J Clin Oncol. 2009;27(12):2007–14.PubMedCrossRef
22.
go back to reference McLaughlin SA, Wright MJ, Morris KT, et al. Prevalence of lymphedema in women with breast cancer 5 years after sentinel lymph node biopsy or axillary dissection: objective measurements. J Clin Oncol. 2008;26(32):5213–19.PubMedCrossRefPubMedCentral McLaughlin SA, Wright MJ, Morris KT, et al. Prevalence of lymphedema in women with breast cancer 5 years after sentinel lymph node biopsy or axillary dissection: objective measurements. J Clin Oncol. 2008;26(32):5213–19.PubMedCrossRefPubMedCentral
23.
go back to reference Fitzmaurice G, Laird N, Ware J. Applied longitudinal data analysis. New Jersey: John Wiley & Sons; 2004. Fitzmaurice G, Laird N, Ware J. Applied longitudinal data analysis. New Jersey: John Wiley & Sons; 2004.
Metadata
Title
Proactive Approach to Lymphedema Risk Reduction: A Prospective Study
Authors
Mei R. Fu, PhD, RN, ACNS-BC, FAAN
Deborah Axelrod, MD, FACS
Amber A. Guth, MD, FACS
Francis Cartwright, PhD, RN-BC
Zeyuan Qiu, PhD
Judith D. Goldberg, ScD
June Kim, MPS
Joan Scagliola, MS, RN
Robin Kleinman, MS, RN
Judith Haber, PhD, RN, APRN-BC, FAAN
Publication date
01-10-2014
Publisher
Springer US
Published in
Annals of Surgical Oncology / Issue 11/2014
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-014-3761-z

Other articles of this Issue 11/2014

Annals of Surgical Oncology 11/2014 Go to the issue